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IGF-I shares structural homology and in vitro metabolic activity
with insulin. Laboratory models suggest that IGF-I and its binding
proteins IGFBP-1 and IGFBP-2 have potentially beneﬁcial effects
on diabetes risk, whereas IGFBP-3 may have adverse effects. We
therefore conducted a prospective nested case-control investiga-
tion of incident diabetes (n = 742 case subjects matched 1:1 to
control subjects) and its associations with IGF-axis protein levels
in the Nurses’ Health Study, a cohort of middle-aged women. The
median time to diabetes was 9 years. Statistical analyses were
adjusted for multiple risk factors, including insulin and C-reactive
protein. Diabetes risk was ﬁvefold lower among women with base-
line IGFBP-2 levels in the top versus bottom quintile (odds ratio
[OR]q5–q1 = 0.17 [95% CI 0.08–0.35]; P trend , 0.0001) and was also
negatively associated with IGFBP-1 levels (ORq5–q1 =0 . 3 7[ 0 . 1 8 –
0.73]; P trend = 0.0009). IGFBP-3 was positively associated with
diabetes (ORq5–q1 =2 . 0 5[ 1 . 2 0 –3.51]; P trend = 0.002). Diabetes was
not associated with total IGF-I levels, but free IGF-I and diabetes
had a signiﬁcant association that varied (P interaction = 0.003)
by insulin levels above the median (ORq5–q1 = 0.48 [0.26–0.90];
P trend = 0.0001) versus below the median (ORq5–q1 = 2.52 [1.05–
6.06]; P trend , 0.05). Thus, this prospective study found strong
associations of incident diabetes with baseline levels of three
IGFBPs and free IGF-I, consistent with hypotheses that the IGF
axis might inﬂuence diabetes risk. Diabetes 61:2248–2254, 2012
I
ncreasing evidence suggests that the insulin-like
growth factor (IGF) axis may play a role in glucose
homeostasis (1). IGF-I shares structural homology
and downstream signaling pathways with insulin,
and like insulin, IGF-I can promote glucose and fatty acid
uptake in peripheral tissues (2). Administration of exoge-
nous IGF-I decreases serum glucose levels and improves
insulin sensitivity in individuals with and without type 2
diabetes (3,4). It has therefore been hypothesized that in-
terindividual heterogeneity in endogenous IGF-I and IGF
binding protein (IGFBP) levels may inﬂuence the risk of
developing type 2 diabetes (5).
Consistent with this, cross-sectional studies by our group
and others have found that individuals with impaired glu-
cose tolerance or diabetes have lower IGFBP-1 and pos-
sibly higher IGFBP-3 levels than healthy individuals (6–8).
A positive association between high IGFBP-3 and diabetes
could be explained by its sequestration of IGF-I. In con-
trast, while IGFBP-1 also sequesters IGF-I, the production
of IGFBP-1 is downregulated by insulin, thus resulting in
low IGFBP-1 levels in patients with preexisting insulin
resistance and hyperinsulinemia (8,9). These relationships
are complicated by the fact that certain IGFBPs may also
have important IGF-independent metabolic activity (5,10,11),
including potentially beneﬁcial effects of IGFBP-1 and
IGFBP-2 on glucose uptake (12,13). IGF-I, conversely, may
have certain adverse metabolic effects (e.g., promoting the
proliferation of preadipocytes) in addition to its beneﬁcial
insulin-like activity (14). Hence, carefully conducted pro-
spective studies are needed to determine the associations
between IGF-axis proteins and the development of diabetes.
To date, few studies have prospectively investigated the
relation of IGF-axis protein levels with incident diabetes.
However, these initial investigations reported intriguing
results (10,15–17). In particular, three of four studies found
that low IGFBP-1 levels were associated with increased
risk of incident diabetes (15–17). Associations between
IGF-I and diabetes were also reported. Two studies found
a positive relation of IGF-I levels with diabetes that were of
borderline statistical signiﬁcance (15,16). A third study,
though, reported an inverse association of IGF-I levels with
impaired glucose tolerance in subjects with low but not
high IGFBP-1—data, suggesting a biologic interaction (10).
The reason for these conﬂicting IGF-I ﬁndings is un-
known. However, prior investigations had relatively few di-
abetic case subjects and involved limited statistical control
for established diabetes risk factors. Furthermore, despite
the prospective collection of data, it is uncertain whether
the associations of IGFBP-1 with diabetes in prior studies
might have reﬂected “reverse causality,” whereby a step in
the disease process (high insulin levels) may have preceded
and caused changes in the exposure of interest (low IGFBP-1
levels in the presence of hyperinsulinemia) (18).
We therefore conducted a large prospective, nested case-
control investigation of the associations between total IGF-I,
free (unbound) IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 and
risk of incident type 2 diabetes in the Nurses’ Health Study
(NHS), a large cohort of middle-aged and older women (19).
The study involved .700 case subjects, controlled for
multiple diabetes risk factors, and involved several steps to
address the possibility of reverse causality.
From the
1Department of Epidemiology and Population Health, Albert Einstein
College of Medicine, Bronx, New York; the
2Department of Medicine, Di-
vision of Endocrinology, Albert Einstein College of Medicine, Bronx, New
York; the
3Department of Nutrition, Harvard School of Public Health, Bos-
ton, Massachusetts; the
4Institute of Occupational Medicine and the Ministry
of Education Key Laboratory of Environment and Health, Tongji Medical
College, Huazhong University of Science and Technology, Wuhan, Hubei,
China; the
5Channing Laboratory, Department of Medicine, Brigham and
Women’s Hospital and Harvard Medical School, Boston, Massachusetts;
the
6Department of Pediatrics, Division of Pediatric Endocrinology, Albert
Einstein College of Medicine, Bronx, New York; the
7Department of Medi-
cine and Oncology, Cancer Prevention Research Unit, Lady Davis Research
Institute of Jewish General Hospital, McGill University, Montreal, Quebec,
Canada; the
8Group Health Research Institute, Fred Hutchinson Cancer Re-
search Center, Seattle, Washington; and the
9Department of Epidemiology,
Harvard School of Public Health, Boston, Massachusetts.
Corresponding author: Howard D. Strickler, howard.strickler@einstein.yu.edu.
Received 28 October 2011 and accepted 19 March 2012.
DOI: 10.2337/db11-1488
F.B.H. and H.D.S., the two senior authors, contributed equally to this study.
 2012 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
2248 DIABETES, VOL. 61, SEPTEMBER 2012 diabetes.diabetesjournals.org
ORIGINAL ARTICLERESEARCH DESIGN AND METHODS
Study population. The NHS is an ongoing longitudinal cohort initiated in 1976
that enrolled 121,700 female registered nurses aged 30–55 years. As described
in detail elsewhere (19), these women are followed on a biennial basis with
mailed questionnaires. During 1989 and 1990, blood specimens were obtained
from 32,826 NHS women who were free of diabetes, coronary heart disease,
stroke, or cancer. Women who subsequently reported a diagnosis of type 2
diabetes were mailed a supplementary questionnaire regarding relevant
symptoms, diagnostic testing, and current treatment. Diabetes was considered
conﬁrmed if the responses matched the criteria of the National Diabetes Data
Group (cases through 1997) or the American Diabetes Association (cases after
1997) (see Table 1 footnotes for detailed deﬁnitions) (20,21). In a validation
study conducted among 84 randomly selected NHS subjects who met the
above criteria, a diagnosis of diabetes was conﬁrmed in 61 (98%) of the 62
individuals for whom medical records were obtained (22).
The current nested case-control investigation involved 742 incident diabetic
case subjects individually matched 1:1 to control subjects using risk-set
sampling (23) based on age (61 year), date of blood draw (63 months),
fasting status (yes/no; 95% of case-control pairs fasted $8 h), and race/
ethnicity. All women signed informed consent forms, and the study pro-
tocol was approved by the institutional review boards of the Brigham and
Women’s Hospital, the Harvard School of Public Health, and the Albert
Einstein College of Medicine.
Laboratoryassays.Laboratory personnel were masked to case-control status,
and specimens from each case-control pair were tested in replicate in the same
assay runs. Total IGF-I, free IGF-I, and IGFBP-1, -2 and -3 levels were measured
using ELISAs from Diagnostic Systems Laboratories (Webster, TX). The av-
erage intra-assay coefﬁcient of variation was ,5% for total IGF-I and the three
IGFBPs and 13% for free IGF-I. C-reactive protein (CRP), insulin, and glyco-
sylated hemoglobin (HbA1c) levels had been previously measured, as reported
(24,25).
Statistical analysis. Case-control differences in selected baseline charac-
teristics were initially assessed using t tests for continuous data and x
2 tests for
categorical data. Correlations between levels of IGF-axis proteins, insulin,
CRP, waist circumference, and BMI were measured in control subjects using
age- and race-adjusted partial Spearman correlation coefﬁcients. Multivariable
conditional logistic regression models were used to estimate the associations
between IGF-axis protein levels and risk of incident diabetes, adjusted for
relevant covariates (23). These covariates included BMI, cigarette smoking
(never smoked, past smoker, or current smoker), menopausal status, hormone
therapy use (never used, past user, or current user), family history of type 2
diabetes (yes/no), physical activity, and intake of alcohol, cereal ﬁber, heme
iron, trans fat, magnesium, coffee, and red meat (all parameterized as quin-
tiles). IGF-axis protein levels in these models were also parameterized as
quintiles, with all quintiles deﬁned according to the distribution of levels
among the control subjects.
Our a priori multivariable models included total or free IGF-I, each of the
three IGFBPs, and each of the above covariates. Insulin and CRP quintiles were
also added tothesemodels to assess their impact on the ﬁndings. Tests of linear
trendwereconductedbyusingthemedianvalueforeachquintileandﬁttingthis
as a continuous variable in the models. Stratiﬁedsubgroup analyses (deﬁned by
levels of HbA1c, insulin, BMI, CRP, and age) were conducted using uncondi-
tional multivariable logistic regression. Two-sided statistical tests were used in
all analyses.
RESULTS
Baseline characteristics. Table 1 shows selected char-
acteristics of case and control subjects at baseline. Given
the matched study design, the two groups, as expected, were
similar with respect to age and race/ethnicity. Compared
with control subjects, however, case subjects had higher
mean BMI and waist circumference, reported lower physical
activity and less alcohol consumption, and were less likely to
use hormone therapy. Case subjects also were more likely
than control subjects to report a family history of diabetes,
a n dt h et w og r o u p sd i f f e r e di nt h e i rc o n s u m p t i o no fs e v e r a l
dietary factors. Moreover, case subjects had signiﬁcantly
higher mean plasma levels of insulin, CRP, and IGFBP-3, as
well as signiﬁcantly lower levels of IGFBP-1 and IGFBP-2.
Mean total and free IGF-I levels did not signiﬁcantly differ
between case and control subjects in these univariate anal-
yses. The mean (median) time from blood draw to the de-
velopment of incident diabetes was 8.4 (9.0) years.
Correlations between biomarkers. Total and free IGF-I
each had a signiﬁcant negative correlation with CRP and a
positive correlation with IGFBP-3 (Table 2), and these
relationships were stronger for total IGF-I than for free
IGF-I. Conversely, free IGF-I had a stronger negative cor-
relation with IGFBP-1 than did total IGF-I, and neither free
nor total IGF-I was signiﬁcantly correlated with IGFBP-2.
IGFBP-2, but not IGFBP-1, had a strong negative correlation
with CRP. Both IGFBP-1 and IGFBP-2, however, had strong
negative correlations with BMI, waist circumference, and
insulin. IGFBP-3 and free IGF-I had weak positive correla-
tions with BMI, waist circumference, and insulin that did
not always reach statistical signiﬁcance.
Associations with type 2 diabetes. Table 3 shows the
results of multivariable conditional logistic regression
models for the relation of IGF-axis protein levels with risk
of diabetes. Total IGF-I was not signiﬁcantly associated
with incident diabetes in our a priori models that adjusted
for the three IGFBPs in addition to multiple diabetes risk
factors (see RESEARCH DESIGN AND METHODS). In contrast, free
IGF-I was inversely associated with diabetes risk in these
models (odds ratio [OR] comparing highest and lowest
quintile [ORq5–q1] = 0.57 [95% CI 0.30–1.08]; P trend = 0.01).
In secondary data analyses, however, we observed a signif-
icant statistical interaction between free IGF-I and insulin
(P interaction = 0.003) (Table 3 and Fig. 1). Speciﬁcally,
among women with baseline insulin levels at or above the
median (i.e., 4.6 mU/mL based on the values in control
subjects), free IGF-I was inversely associated with diabetes
risk (ORq5–q1 =0 . 4 8[ 0 . 2 6 –0.90]; P trend = 0.0001). In those
with insulin levels below the median, free IGF-I was posi-
tively associated with incident diabetes (ORq5–q1 =2 . 5 2
[1.05–6.06]; P trend , 0.05). Additional adjustment for in-
sulin (as a continuous variable within each of the two
strata) and CRP quintile did not alter the ﬁndings of this
subanalysis, nor did using insulin cut points other than the
median. Excluding cases of diabetes that occurred within
2 years of baseline (i.e., a 2-year lag time) also had no
meaningful affect on these results.
IGFBP-1 and IGFBP-2 levels had strong inverse associa-
tions with risk of diabetes in the same a priori models de-
scribed above (Table 3). The ORq5–q1 for IGFBP-1 was 0.37
(95% CI 0.18–0.73; P trend = 0.0009), and for IGFBP-2, the
ORq5–q1 was 0.17 (0.08–0.35; P trend , 0.0001)—am o r e
than ﬁvefold association with diabetes risk. IGFBP-3 levels
were positively associated with development of incident
t y p e2d i a b e t e s( O R q5–q1 = 2.05 [1.20–3.51]; P trend = 0.002).
Additional adjustment for CRP and insulin did not mean-
ingfully change the associations of diabetes with IGFBP-1,
-2, or -3. Unlike for free IGF-I, the associations between
diabetes and IGFBP-1, -2, and -3 also did not vary by insulin
values above versus below the median (see Fig. 1). None of
the IGFBP results were meaningfully changed by excluding
cases of diabetes that occurred within 2 years of enrollment.
Because IGFBP-1 and IGFBP-2 are both partly regulated
by insulin, we took additional steps to assess whether in-
sulin resistance at baseline might have affected these
ﬁndings. Speciﬁcally, we restricted analysis to women who
not only had insulin levels below the median but also had
HbA1c levels within the normal range of ,5.7% (26). The
mean (median) time from blood draw to development of
incident diabetes was 11.1 (11.2) years in these subjects.
The associations of IGFBP-1 (ORq5–q1 = 0.21 [95% CI 0.08–
0.57]; P trend = 0.009) and IGFBP-2 (ORq5–q1 = 0.16 [0.06–
0.42]; P trend = 0.0001) were not, however, meaningfully
altered.
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tical interaction) in the associations between diabetes and
IGF-axis protein levels was observed according to median
age, BMI, or CRP levels (data not shown). The ﬁndings for
total and free IGF-I did not vary by median IGFBP levels,
and the ﬁndings for IGFBP-1, -2, and -3 did not vary by IGF-I
levels. Only one potential interaction was observed: free
IGF-I had an inverse association of borderline statistical
signiﬁcance with diabetes risk among women with IGFBP-1
levels below the median (ORq5–q1 =0 . 6 9[ 9 5 %C I0 . 3 6 –1.33];
P trend = 0.07) but had no association with diabetes when
IGFBP-1 levels were at or above the median (P interaction
= 0.09). No results in the study were meaningfully changed
by restricting analysis to the 95% of case-control pairs who
had fasted for at least 8 h before blood collection.
DISCUSSION
To our knowledge, this is the ﬁrst large prospective study
to assess multiple components of the IGF axis and their
associations with risk of incident type 2 diabetes. Free
IGF-I and IGFBP-1, IGFBP-2, and IGFBP-3 each had sig-
niﬁcant independent associations with diabetes risk. These
associations remained signiﬁcant even after control for
important molecular and other established diabetes risk
factors. Moreover, the OR estimates for all three IGFBPs
were strong and showed a biologic gradient, gaining in
strength with increasing quintile. There was, for example,
a more than ﬁvefold reduction in risk between the highest
and lowest quintiles of IGFBP-2 and a nearly threefold
reduction in risk associated with the IGFBP-1 quintile.
Considering the large fraction of participants in high- or
moderate-risk IGFBP strata, these relationships could
have important clinical and public health implications.
TABLE 1
Baseline characteristics of women who developed incident type 2 diabetes* and matched control subjects in the NHS
Characteristic Case subject (n = 742) Control subject (n = 742) P value†
Demography and lifestyle
Age (years) 56.2 (7.0) 56.3 (7.0) —§
White 81.9 83.0 —§
Current smoker 13.3 11.1 0.38
Postmenopausal 78.6 78.0 0.80
Current hormone use 29.5 41.2 ,0.0001
Family history of diabetes 44.2 23.1 ,0.0001
BMI (kg/m
2) 29.6 (5.3) 24.9 (4.1) ,0.0001
Waist circumference (cm) 88.2 (11.9) 77.1 (9.8) ,0.0001
Physical activity (MET hour/week) 14.7 (16.0) 17.8 (17.4) 0.0004
Alcohol (g/day) 4.0 (7.4) 6.4 (9.2) ,0.0001
Diet
Fruits and vegetables (servings/day) 5.2 (1.9) 5.3 (2.0) 0.41
Red meat (servings/day) 1.2 (0.5) 1.0 (0.5) ,0.0001
Fish (servings/week) 0.28 (0.17) 0.25 (0.16) 0.003
Cereal ﬁber (g/day) 3.8 (1.6) 4.2 (1.7) 0.0002
Whole grain (g/day) 15.0 (10.5) 17.3 (11.7) ,0.0001
Total energy (kcal/day) 1,803 (534) 1,756 (482) 0.08
Biomarkers
Insulin (mU/mL) 10.3 (7.9) 6.0 (4.1) ,0.0001
CRP (mg/dL) 0.51 (0.52) 0.24 (0.29) ,0.0001
Total IGF-I (ng/mL) 151 (50) 151 (50) 0.96
Free IGF-I (ng/mL) 0.48 (0.30) 0.46 (0.28) 0.16
IGFBP-1 (ng/mL) 24.2 (23.6) 42.9 (29.0) ,0.0001
IGFBP-2 (ng/mL) 335 (229) 584 (342) ,0.0001
IGFBP-3 (ng/mL) 5,060 (1,262) 4,641 (980) ,0.0001
For continuous variables, values are expressed as mean (SD); for categorical variables, values are proportions (%). *A self-reported case of
diabetes was considered conﬁrmed if in a supplementary questionnaire the subject reported information consistent with the National Diabetes
Data Group (NDDG) criteria (for those NHS cases reported through 1997) or consistent with the American Diabetes Association (ADA)
criteria (for those NHS cases reported after 1997). Speciﬁcally, under the NDDG criteria, diabetes was diagnosed if the subject reported at
least one of the following: 1) polydipsia, polyuria, polyphagia, weight loss, or coma, in addition to a fasting glucose level $140 mg/dL or
a random level $200 mg/dL; 2) in the absence of symptoms, elevated plasma glucose concentrations on at least two occasions, including
a fasting glucose $140 mg/dL, a random glucose $200 mg/dL, or after $2 h during a oral glucose test, a glucose $200 mg/dL; 3) treatment
with oral drugs for hyperglycemia or with insulin. For cases of diabetes reported after 1997, the diagnosis was conﬁrmed using new
recommendations of the ADA, which changed the fasting glucose cutoff to 126 mg/dL. †P values for differences between case and control
subjects (unadjusted) were determined by Student t test for continuous variables and x
2 test for categorical variables. §Matching factor.
TABLE 2
Age- and race-adjusted partial correlation coefﬁcients between
IGF-I, IGFBPs, and selected other risk factors for type 2 diabetes
among the 742 control subjects
Total IGF-I Free IGF-I IGFBP-1 IGFBP-2 IGFBP-3
BMI 0.02 0.09† 20.47* 20.42* 0.11†
Waist 0.04 0.08† 20.36* 20.26* 0.11†
Insulin 0.06 0.06 20.36* 20.32* 0.10†
CRP 20.34* 20.23* 20.07 20.43* 20.10
IGFBP-3 0.62* 0.22* 20.21* 20.21* —
IGFBP-2 0.01 0.02 0.32* ——
IGFBP-1 20.28* 20.41* ———
Free IGF-I 0.53* — ———
*P , 0.001. †P , 0.05.
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glucose homeostasis in part because IGFBP-1 production
is downregulated by insulin. IGFBP-2 production is also
inhibited by insulin, although the effect occurs more slowly
(11,27). Consistent with this, our data showed negative
correlations between levels of insulin and those of IGFBP-1
and IGFBP-2. These correlations, though, also raised the
possibility of reverse causality (i.e., that the apparent
associations of low IGFBP-1 and IGFBP-2 levels with di-
abetes might be explained by a greater frequency of high
insulin levels, for example, related to insulin resistance,
among case subjects than control subjects at baseline,
rather than by a biologic role of these IGFBPs in diabetes
pathogenesis). In the current study, however, we showed
that the strong relation of IGFBP-1 and IGFBP-2 with di-
abetes was essentially unchanged by restricting the analysis
to women who at baseline had both low insulin and normal
HbA1c levels—a subgroup with very low probability of
preexisting insulin resistance. In these women, diabetes
occurred a median of 11 years after blood draw.
Furthermore, the current IGFBP-1 results are consistent
with those of prior epidemiologic studies. Three of four earlier
prospective studies reported inverse associations between
high IGFBP-1 levels and risk of diabetes (15–17). While no
prior prospective studies examine the relation of IGFBP-2 or
IGFBP-3 with diabetes, we previously reported cross-sectional
data showing a possible positive association of IGFBP-3 levels
with diabetes and impaired glucose tolerance (6).
TABLE 3
ORs (95% CIs) for incident type 2 diabetes, according to quintile of IGF-I and its binding proteins*
Quintile of baseline plasma level†
P trend‡ 12 3 4 5
Total IGF-I
Case subjects (n) 147 155 136 153 151
Multivariable model 1.0 1.29 (0.80–2.08) 1.03 (0.63–1.70) 1.50 (0.92–2.44) 1.49 (0.87–2.54) 0.12
Model + IGFBP-1 + IGFBP-2 +
IGFBP-3 (a priori model) 1.0 0.84 (0.47–1.49) 0.68 (0.36–1.27) 0.69 (0.36–1.35) 0.58 (0.28–1.22) 0.11
Model + IGFBP-1 + IGFBP-2 +
IGFBP-3 + CRP + insulin 1.0 0.85 (0.46–1.56) 0.71 (0.36–1.41) 0.77 (0.37–1.60) 0.70 (0.31–1.58) 0.38
Free IGF-I
Case subjects (n) 119 160 166 137 159
Multivariable model 1.0 1.28 (0.79–2.09) 1.16 (0.71–1.90) 1.02 (0.59–1.76) 1.11 (0.66–1.85) 0.97
Model + IGFBP-1 + IGFBP-2 +
IGFBP-3 (a priori model) 1.0 1.06 (0.61–1.84) 0.72 (0.40–1.29) 0.47 (0.24–0.92) 0.57 (0.30–1.08) 0.01
Model + IGFBP-1 + IGFBP-2 +
IGFBP-3 + CRP + insulin 1.0 1.16 (0.64–2.09) 0.84 (0.45–1.57) 0.53 (0.26–1.08) 0.67 (0.34–1.34) 0.04
(,Median insulin level) Model +
IGFBP-1 + IGFBP-2 + IGFBP-3§ 1.0 1.12 (0.48–2.64) 1.50 (0.61–3.70) 1.53 (0.68–3.47) 2.52 (1.05–6.06) ,0.05
($Median insulin level) Model +
IGFBP-1 + IGFBP-2 + IGFBP-3§ 1.0 1.28 (0.72–2.28) 0.82 (0.46–1.46) 0.50 (0.27–0.92) 0.48 (0.26–0.90) 0.0001
IGFBP-1
Case subjects (n) 400 153 73 73 43
Multivariable model 1.0 0.51 (0.33–0.80) 0.39 (0.24–0.64) 0.30 (0.18–0.51) 0.22 (0.12–0.39) ,0.0001
Model + free IGF-I + IGFBP-2 +
IGFBP-3 (a priori model) 1.0 0.72 (0.44–1.18) 0.58 (0.33–1.01) 0.46 (0.25–0.85) 0.37 (0.18–0.73) 0.0009
Model + free IGF-I + IGFBP-2 +
IGFBP-3 + CRP + insulin 1.0 0.71 (0.43–1.20) 0.63 (0.35–1.16) 0.51 (0.26–1.00) 0.42 (0.20–0.90) 0.01
IGFBP-2
Case subjects (n) 407 156 103 49 27
Multivariable model 1.0 0.41 (0.26–0.63) 0.31 (0.19–0.51) 0.15 (0.08–0.27) 0.11 (0.06–0.22) ,0.0001
Model + free IGF-I + IGFBP-1 +
IGFBP-3 (a priori model) 1.0 0.52 (0.33–0.82) 0.45 (0.26–0.76) 0.23 (0.12–0.43) 0.17 (0.08–0.35) ,0.0001
Model + free IGF-I + IGFBP-1 +
IGFBP-3 + CRP + insulin 1.0 0.54 (0.32–0.90) 0.49 (0.28–0.88) 0.25 (0.13–0.50) 0.19 (0.09–0.41) ,0.0001
IGFBP-3
Case subjects (n) 105 103 99 175 260
Multivariable model 1.0 1.33 (0.78–2.25) 1.16 (0.68–1.99) 2.40 (1.47–3.91) 2.63 (1.64–4.22) ,0.0001
Model + free IGF-I + IGFBP-1 +
IGFBP-2 (a priori model) 1.0 1.27 (0.71–2.26) 1.23 (0.69–2.20) 2.00 (1.16–3.42) 2.05 (1.20–3.51) 0.002
Model + free IGF-I + IGFBP-1 +
IGFBP-2 + CRP + insulin 1.0 1.46 (0.78–2.72) 1.31 (0.72–2.40) 2.22 (1.25–3.96) 2.07 (1.16–3.71) 0.004
Data are OR (95% CI) unless otherwise indicated. *The initial multivariable model conditioned on matching factors and adjusted for BMI,
smoking status (never smoked, past smoker, or current smoker), postmenopausal status (yes/no), hormone use (never used, past user, or
current user), family history of diabetes (yes/no), physical activity (in quintiles), and intake of alcohol, cereal ﬁber, heme iron, trans fat,
magnesium, coffee, and red meat (all in quintiles). †Quintiles were determined using the distribution among control subjects, and quintile 1
served as a reference group for the estimation of each OR. ‡Tests of linear trend were conducted by assigning the median value for each
quintile and ﬁtting this as a continuous variable in the models. §These analyses were stratiﬁed by insulin levels less than vs. equal to or above
the median measured in control subjects (i.e., 4.6 mU/mL) and were conducted using unconditional multivariate logistic regression models
that incorporated the matching factors as well as all the above covariates.
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with the current ﬁndings. For example, in vitro models
show that IGFBP-1 and IGFBP-2 inhibit preadipocyte
proliferation and differentiation (11,13), and in mouse
models, the overexpression of IGFBP-2 was associated
with decreased susceptibility to obesity and improved
insulin sensitivity (12,13). IGFBP-1 overexpression also
lowered susceptibility to obesity in rodent models (28,29)
and was associated with decreased risk of insulin re-
sistance in a mouse model that accounted for the lower
IGF afﬁnity of nonphosphorylated than phosphorylated
IGFBP-1 (a difference that is found in humans but not
rodents) (11,30,31). Furthermore, IGFBP-1 and IGFBP-2
have both been shown to bind a5b1-integrin receptors on
cell surfaces, thereby activating the phosphatidylinositol
3-kinase and protein kinase B signaling pathway, result-
ing in intracellular translocation of GLUT4 and increased
glucose uptake (11,32,33).
IGFBP-3 had a positive association with diabetes risk in
this study and this too was in keeping with laboratory data.
IGFBP-3 is the most abundant IGFBP in circulation and
binds .90% of all circulating IGF-I (34). Furthermore,
IGFBP-3 binds cellular proteins involved in the regulation
of glucose metabolism, such as 9-cis retinoic acid re-
ceptor-a (34–36), and can induce hepatic insulin resistance
and lower glucose uptake in muscle and adipose tissue
(37,38).
Free IGF-I, unlike IGFBP-1, -2, and -3, had an association
with diabetes that varied with insulin and to a lesser ex-
tent, with IGFBP-1 levels; these results shared similarity
with previously reported IGF-I data. Sandhu et al. (10), for
example, found that high IGF-I levels were associated with
lower risk of impaired glucose tolerance among those with
IGFBP-1 levels below but not above the median. In the
current study, we observed an inverse association of bor-
derline statistical signiﬁcance between free IGF-I and di-
abetes that likewise was limited to women with IGFBP-1
levels below the median. In a separate model, we also
observed a signiﬁcant inverse association of free IGF-I and
diabetes limited to women with insulin levels above the
median. Given that insulin downregulates IGFBP-1 pro-
duction, these two interactions could be related, albeit
even larger studies or data from multiple cohorts would
be needed to examine both interactions simultaneously.
Lewitt et al. (15,16), in contrast, reported positive associ-
ations of borderline signiﬁcance between IGF-I and risk of
diabetes (10). It is notable, therefore, that among women
with insulin levels below the median, we found a positive
association of free IGF-I and diabetes risk, unlike the in-
verse association found when insulin levels were greater
than the median (discussed above). Thus, the effects of
IGF-I may vary according to the baseline characteristics of
the patient population (e.g., baseline insulin levels).
Overall, the collective data raise the possibility that the
relation of IGF-I with diabetes risk may be bimodal. For
example, among patients with preexisting insulin resis-
tance, the insulin-like activity of IGF-I on glucose and free
fatty acid uptake may play an important role in glucose
homeostasis. Consistent with this, laboratory studies have
shown that in the presence of insulin resistance, there is
upregulation of insulin/IGF hybrid receptor expression in
muscle (39,40). These receptors are largely responsive to
IGF-I (40), and additional data suggest that their binding
could be as potent in stimulating peripheral glucose uptake
as insulin binding with its receptor (41). Correspondingly,
transgenic mouse studies have shown that a muscle-speciﬁc
dominant-negative IGF-I receptor mutation results in de-
fective hybrid receptors and the development of diabetes by
6 weeks of age (42–44). It is noteworthy, therefore, that
obesity may be associated with moderate elevation of free
IGF-I levels (5,8,45,46), as reﬂected by the positive corre-
lation of free IGF-I and BMI in the current study. This can
occur despite the relation of obesity with hyposecretion of
growth hormone (GH) (47), the primary regulator of IGF-I
production by the liver (48), because of IGF-I production by
adipocytes (49) and the stimulation of hepatic IGF-I syn-
thesis by insulin (27). Collectively, high circulating levels of
free IGF-I and upregulation of hybrid receptor expression in
muscle tissue in obese compared with normal weight indi-
viduals could accentuate the beneﬁcial metabolic effects of
FIG. 1. Associations of incident diabetes with IGF-axis protein levels (highest vs. lowest quintile) stratiﬁed by insulin levels above and below the
median. All associations (ORs) were adjusted for covariates using multivariable logistic regression models (as reported in Table 3). Median insulin
level was determined using values among control subjects (i.e., 4.61 mU/mL). Vertical lines represent 95% CIs.
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production via a negative-feedback loop, and by reducing
circulating GH levels, it may reduce the anti-insulin effects
of GH (45,50). Through either one or both of these mech-
anisms, free IGF-I may therefore have beneﬁcial effects on
glucose homeostasis in obese and other patients with pre-
existing insulin resistance (5).
Prior to the development of insulin resistance, however,
the adverse metabolic effects of IGF-I may predominate.
For example, IGF-I promotes preadipocyte differentiation
and proliferation through activation of the insulin receptor
substrate and mitogen-activated protein kinase pathways
(14,29). Mouse models, concordantly, have shown that re-
duction of IGF-I receptor expression in adipose tissue
(29,51) or targeted inactivation of hepatic IGF-I expression
(52) results in a reduction in adipose tissue. Furthermore,
the relationship between IGF-axis signaling and adiposity
may be depot speciﬁc, with a greater affect of IGF-I on the
differentiation of visceral than subcutaneous adipocytes
(53). Insulin resistance is more strongly associated with
visceral than subcutaneous adiposity (54). Thus, in women
and men who are not currently obese, IGF-I signaling could
promote visceral adiposity and increased risk of diabetes.
Despite several areas of concordance between our study
and prior epidemiologic and laboratory data, there are
limitations to the current investigation that must be con-
sidered in its interpretation. First, unlike both Sandhu et al.
(10) and Lewitt et al. (15,16), we did not observe a relation
of diabetes with total IGF-I, only a relation of diabetes with
free IGF-I. Conversely, none of the prior prospective
studies measure free IGF-I, and it is free (unbound) IGF-I
that is thought to be the most bioactive component of total
IGF-I (55). We had in fact predicted stronger, more con-
sistent associations with free IGF-I than with total IGF-I
because our earlier studies of cancer found disease asso-
ciations with free but not total IGF-I (56,57). Other limi-
tations must also be considered. Although we assessed
HbA1c and fasting insulin, we did not measure other indi-
cators of normoglycemia or insulin resistance, such as ho-
meostasis model assessment–estimated insulin resistance
or oral glucose tolerance. Despite our efforts to address
confounding and reverse causality, we cannot exclude the
possibility that one or both may have affected our results.
We also cannot exclude the possibility that chance ﬁndings
might explain the statistical interaction between free IGF-I
and insulin. Lastly, the current study included predominantly
Caucasian women, and the results may not be generalizable
to men or to other racial/ethnic groups.
In conclusion, the ﬁndings of this large prospective
study suggest that IGFBP-1 and IGFBP-2 have strong inverse
associations with risk of type 2 diabetes risk in women,
whereas IGFBP-3 is associated with increased risk, and the
relation of free IGF-I and diabetes may vary by insulin levels.
These results provide important new evidence that circu-
lating IGF-axis proteins may have a biologic role in the
pathogenesis of type 2 diabetes. Moreover, if these strong
associations are conﬁrmed, IGF-axis proteins may be useful
in diabetes risk stratiﬁcation (e.g., in combination with other
biomarkers) and could represent targets for the develop-
ment of new chemoprevention or treatment strategies.
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